Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: A review

Rafia Sultana Rasu, Tonya Crawford, Harold J. Manley, Rajesh Balkrishnan

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Hypertension and diabetes mellitus are the two leading causes of chronic kidney disease (CKD). The purpose of this paper is to provide an overview of the present pharmacologic and adverse events involved in the treatment of hypertension and diabetes mellitus in patients with CKD. Proper management of hypertension and diabetes mellitus, a common co-morbidity associated with CKD, would slow the progression of kidney disease and reduce healthcare expenditures. Awareness of potential side effects due to the medications or renal insufficiency could prevent unnecessary harm to the patient and provide cost-containment. Active involvement of all healthcare team members can reduce progression of CKD and improve quality of life outcomes in CKD patients.

Original languageEnglish
Pages (from-to)2543-2551
Number of pages9
JournalExpert Opinion on Pharmacotherapy
Volume8
Issue number15
DOIs
StatePublished - 1 Oct 2007

Fingerprint

Chronic Renal Insufficiency
Diabetes Mellitus
Hypertension
Patient Harm
Therapeutics
Patient Care Team
Cost Control
Kidney Diseases
Health Expenditures
Renal Insufficiency
Quality of Life
Morbidity
Delivery of Health Care

Keywords

  • ACE-I
  • ARB
  • Chronic kidney disease
  • Costs
  • Diabetes mellitus
  • Hypertension
  • Quality of life

Cite this

Rasu, Rafia Sultana ; Crawford, Tonya ; Manley, Harold J. ; Balkrishnan, Rajesh. / Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease : A review. In: Expert Opinion on Pharmacotherapy. 2007 ; Vol. 8, No. 15. pp. 2543-2551.
@article{e45b982d28224d56a077845117c74609,
title = "Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease: A review",
abstract = "Hypertension and diabetes mellitus are the two leading causes of chronic kidney disease (CKD). The purpose of this paper is to provide an overview of the present pharmacologic and adverse events involved in the treatment of hypertension and diabetes mellitus in patients with CKD. Proper management of hypertension and diabetes mellitus, a common co-morbidity associated with CKD, would slow the progression of kidney disease and reduce healthcare expenditures. Awareness of potential side effects due to the medications or renal insufficiency could prevent unnecessary harm to the patient and provide cost-containment. Active involvement of all healthcare team members can reduce progression of CKD and improve quality of life outcomes in CKD patients.",
keywords = "ACE-I, ARB, Chronic kidney disease, Costs, Diabetes mellitus, Hypertension, Quality of life",
author = "Rasu, {Rafia Sultana} and Tonya Crawford and Manley, {Harold J.} and Rajesh Balkrishnan",
year = "2007",
month = "10",
day = "1",
doi = "10.1517/14656566.8.15.2543",
language = "English",
volume = "8",
pages = "2543--2551",
journal = "Expert Opinion on Pharmacotherapy",
issn = "1465-6566",
publisher = "Taylor and Francis Ltd.",
number = "15",

}

Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease : A review. / Rasu, Rafia Sultana; Crawford, Tonya; Manley, Harold J.; Balkrishnan, Rajesh.

In: Expert Opinion on Pharmacotherapy, Vol. 8, No. 15, 01.10.2007, p. 2543-2551.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Treatment of hypertension and diabetes mellitus in patients with chronic kidney disease

T2 - A review

AU - Rasu, Rafia Sultana

AU - Crawford, Tonya

AU - Manley, Harold J.

AU - Balkrishnan, Rajesh

PY - 2007/10/1

Y1 - 2007/10/1

N2 - Hypertension and diabetes mellitus are the two leading causes of chronic kidney disease (CKD). The purpose of this paper is to provide an overview of the present pharmacologic and adverse events involved in the treatment of hypertension and diabetes mellitus in patients with CKD. Proper management of hypertension and diabetes mellitus, a common co-morbidity associated with CKD, would slow the progression of kidney disease and reduce healthcare expenditures. Awareness of potential side effects due to the medications or renal insufficiency could prevent unnecessary harm to the patient and provide cost-containment. Active involvement of all healthcare team members can reduce progression of CKD and improve quality of life outcomes in CKD patients.

AB - Hypertension and diabetes mellitus are the two leading causes of chronic kidney disease (CKD). The purpose of this paper is to provide an overview of the present pharmacologic and adverse events involved in the treatment of hypertension and diabetes mellitus in patients with CKD. Proper management of hypertension and diabetes mellitus, a common co-morbidity associated with CKD, would slow the progression of kidney disease and reduce healthcare expenditures. Awareness of potential side effects due to the medications or renal insufficiency could prevent unnecessary harm to the patient and provide cost-containment. Active involvement of all healthcare team members can reduce progression of CKD and improve quality of life outcomes in CKD patients.

KW - ACE-I

KW - ARB

KW - Chronic kidney disease

KW - Costs

KW - Diabetes mellitus

KW - Hypertension

KW - Quality of life

UR - http://www.scopus.com/inward/record.url?scp=35748957810&partnerID=8YFLogxK

U2 - 10.1517/14656566.8.15.2543

DO - 10.1517/14656566.8.15.2543

M3 - Review article

C2 - 17931089

AN - SCOPUS:35748957810

VL - 8

SP - 2543

EP - 2551

JO - Expert Opinion on Pharmacotherapy

JF - Expert Opinion on Pharmacotherapy

SN - 1465-6566

IS - 15

ER -